U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C37H39NO4
Molecular Weight 561.7099
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DAPITANT

SMILES

COC1=CC=CC=C1[C@H](C)C(=O)N2C[C@@H]3[C@H](C2)C(CC[C@@]3(O)C4=CC=CC=C4OC)(C5=CC=CC=C5)C6=CC=CC=C6

InChI

InChIKey=CCIWVEMVBWEMCY-RCFOMQFPSA-N
InChI=1S/C37H39NO4/c1-26(29-18-10-12-20-33(29)41-2)35(39)38-24-31-32(25-38)37(40,30-19-11-13-21-34(30)42-3)23-22-36(31,27-14-6-4-7-15-27)28-16-8-5-9-17-28/h4-21,26,31-32,40H,22-25H2,1-3H3/t26-,31-,32+,37+/m0/s1

HIDE SMILES / InChI

Molecular Formula C37H39NO4
Molecular Weight 561.7099
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Dapitant is an antagonist of neurokinin 1 (NK1) receptor, discovered by the French company Rhône-Poulenc Rorer. NK1 receptors are thought to mediate the neurogenic inflammatory effects of substance P. Dapitant demonstrated efficacy as an antimigraine agent in several animal models. However, in a global, double-blind, randomize, placebo-controlled trial in patients with migraine attacks with moderate or severe headache intensity, treatment with dapitant did not lead to an improvement in the intensity of headache, and the development of the drug was discontinued.

Approval Year

PubMed

Substance Class Chemical
Record UNII
NRD5XF638P
Record Status Validated (UNII)
Record Version